The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity in osteosarcoma patients treated with high cumulative dose of doxorubicin - Egyptian Knowledge Bank

42806

The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity in osteosarcoma patients treated with high cumulative dose of doxorubicin

Thesis

Last updated: 06 Feb 2023

Overview Similar Items

Thesis

Risk stratification of early cardiotoxicity In children receiving chemotherapy in pediatric oncology

Thesis

Study the effect of oral deferiprone and subcutaneous desferoxamine on ventricular function in thalassemia major

Thesis

Clinical, echocardiographic and laboratory assessment of the cardioprotective effect of deferoxamine in patients undergoing CABG

Thesis

Recent insight about oral iron chelators

Thesis

Cardiotoxicity induced by anti-cancer drugs

Thesis

Recent modalities : Tissue Doppler and 2-D speckle tracking echocardiography for diagnosis of anthracycline induced cardiotoxicity in children

Thesis

The role of Troponin I in the early detection of anthracycline-induced cardiotoxicity

Thesis

Modalities of iron chelation in Egyptian thalassemia major patients

Thesis

Organ iron levels as a marker in cases of iron overload

Thesis

Experimental study of the cardioprotective effect of captopril and fosinopril versus vitamin e on doxorubicin cardiotoxicity